Excipient Change Is Not a Purchasing Task

Excipient Change Is Not a Purchasing Task

Changing an excipient sounds simple until it is real.

Find another material.

Qualify a supplier.

Update the specification.

Run the testing.

Check the filing impact.

Confirm stability.

Make sure production can actually use it.

Then try to do all of that while the business asks whether this can be done by next Thursday.

Sure.

Nothing concerning there.

FDA and USP's carbomer activity is a useful reminder that ingredient changes are rarely just ingredient changes.

FDA has alerted drug manufacturers to the risk of benzene contamination in certain drugs containing carbomers manufactured with benzene. FDA also issued guidance on reformulating drug products that contain carbomers manufactured with benzene.

USP announced notices of intent to omit five carbomer monographs for carbomers manufactured with benzene and identified August 1, 2026 as the targeted official date for those omissions.

That is the source fact pattern.

The operator lesson is broader:

An excipient change is not a purchasing task.

It is a quality-system event.

The Material Is Only the First Question

When an ingredient creates a risk, the first instinct is understandable.

Find another one.

But the replacement material is only the start of the work.

Who makes it?

How is it made?

What solvent system or process risk applies?

What specifications change?

What impurities matter?

What analytical methods need confirmation?

What supplier qualification evidence is enough?

What happens to the formulation?

What happens to the process?

What happens to stability?

What happens to the filing?

That is not procurement.

That is lifecycle control.

Procurement can help source the option.

Quality, Regulatory, Formulation, Validation, Supply Chain, and Operations have to decide whether the option is actually usable.

The Shortcut Is Where the Risk Hides

The pressure in these situations is predictable.

Everyone wants the cleaner material.

Everyone wants continuity of supply.

Everyone wants to avoid a regulatory delay.

Everyone wants the change control closed.

That is when shortcuts start sounding reasonable.

The supplier has a good certificate.

The material is compendial.

The function is the same.

The formulation impact should be minor.

The current method probably still works.

The stability risk seems low.

Maybe all of that is true.

Maybe.

But "probably" is not a control strategy.

A material change has to be evaluated against the actual product, process, use, route, patient risk, and regulatory commitments.

Otherwise the company may solve one problem and quietly create three more.

Change Control Has to Connect the Work

Good change control is not a form routing exercise.

It is how the organization keeps the story connected.

For an excipient transition, the change control has to tie together:

• Supplier qualification
• Material specifications
• Impurity and contamination risk
• Analytical method suitability
• Formulation performance
• Manufacturing process impact
• Cleaning and cross-contamination considerations
• Stability strategy
• Regulatory and labeling impact
• Inventory transition and batch-release controls
• Customer or market communication needs, if applicable

That list is not meant to make the work heavier.

It is meant to keep the work from becoming fragmented.

Fragmented changes are dangerous because every function sees its piece and assumes someone else has the whole picture.

Usually no one does.

That is how surprises get manufactured.

Supplier Qualification Is Not a One-Time Badge

Supplier qualification is often treated like a gate.

Approved or not approved.

Green or red.

Move on.

That is not enough when the material is changing because of a known risk.

The organization needs to understand why the new supplier and material are acceptable for this use.

What changed from the prior material?

What evidence supports the new material?

What controls prevent the same risk from reappearing?

What monitoring will continue after approval?

What happens if supply tightens and purchasing wants a backup source?

The supplier file should not just prove someone completed the checklist.

It should prove the company understands the risk it is accepting.

Stability Is Where Optimism Goes to Be Tested

A replacement excipient may look fine in development data.

It may process cleanly.

It may meet release specifications.

It may make everyone feel like the change is under control.

Then stability gets a vote.

Stability is where assumptions become evidence or become problems.

That is why the plan cannot be an afterthought.

What batches support the change?

What container-closure system is representative?

What attributes could shift?

What accelerated or long-term data is needed?

What happens to expiry?

What is the release strategy while data matures?

These are not academic questions.

They are the difference between a controlled transition and a future deviation with better lighting.

Regulatory Needs a Seat Early

Regulatory impact should not be discovered after the technical team has already fallen in love with the solution.

That is not alignment.

That is cleanup.

Depending on the product and market, an excipient change may affect filings, commitments, labeling, prior approvals, supplements, annual reports, or customer expectations.

The right answer depends on the product and regulatory pathway.

The wrong answer is waiting until the end and asking Regulatory to bless the path because the business already promised a date.

Dates are not strategy.

They are pressure with a calendar.

The Operator Test

If your team is handling an excipient transition, ask the practical questions.

Can we explain why this change is needed?

Can we trace the risk from source material to finished product?

Can we show supplier evidence that actually addresses the risk?

Can we prove the new material works in our formulation and process?

Can we defend the analytical and stability strategy?

Can we explain the regulatory path before we execute?

Can batch release tell which material, supplier, and control strategy applied?

Can the site run the transition without mixing old assumptions with new material?

If those answers are unclear, the change is not ready.

The purchase order may be ready.

The quality system is not.

The Work Is Cross-Functional Because the Risk Is Cross-Functional

Excipient changes touch more than one department because excipients touch the product in more than one way.

They affect formulation.

They affect manufacturing.

They affect testing.

They affect stability.

They affect supplier control.

They can affect regulatory strategy.

So the work has to be led across functions, not tossed over the wall from one group to the next.

That is where practical leadership matters.

Someone has to own the whole path.

Someone has to keep the functions aligned.

Someone has to make sure speed does not outrun evidence.

Someone has to know when "close enough" is not good enough.

That is the difference between changing a material and controlling a change.

And in pharma, only one of those is acceptable.

Website Publishing Notes

• Stage as Squarespace draft only.
• Set author to Two Pharma Guys.
• Add source URLs in the post settings or internal source note where available.
• Use the hero image and alt text provided above.
• Do not publish until Micah approves.